Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Big pharma interest remains, but the mood is fast turning gloomy.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
After menin, the company tries again with farnesyl transferase.